

Dinesh Khanna

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7857016/dinesh-khanna-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

418
papers

25,226
citations

69
h-index

147
g-index

446
ext. papers

31,670
ext. citations

5.2
avg. IF

6.89
L-index

#	Paper	IF	Citations
418	Reliability, validity, and responsiveness to change of the Patient-Reported Outcomes Measurement Information System self-efficacy for managing chronic conditions measure in systemic sclerosis.. <i>Journal of Scleroderma and Related Disorders</i> , 2022 , 7, 110-116	2.3	
417	Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 19	5.7	1
416	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition.. <i>Journal of Scleroderma and Related Disorders</i> , 2022 , 7, 24-32	2.3	5
415	Biologics in Systemic Sclerosis 2022 , 85-99		
414	Functional Characterization of Glycoprotein Nonmetastatic Melanoma Protein B in Scleroderma Fibrosis.. <i>Frontiers in Immunology</i> , 2022 , 13, 814533	8.4	0
413	Management of scleroderma gastrointestinal disease: Lights and shadows.. <i>Journal of Scleroderma and Related Disorders</i> , 2022 , 7, 85-97	2.3	1
412	Symptom experience of limited cutaneous systemic sclerosis from the Patients' perspective: A qualitative study. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 52, 151926-151926	5.3	1
411	Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USA. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 131, 43-51	2.2	
410	Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open Label Extension of a Phase 3 Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 ,	10.2	5
409	Interpretation of PFTs and Decline in PFTs. <i>In Clinical Practice</i> , 2021 , 139-149	0	
408	STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease. <i>Journal of Rheumatology</i> , 2021 , 48, 1295-1298	4.1	4
407	Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries. <i>Arthritis and Rheumatology</i> , 2021 , 73, 837-847	9.5	9
406	Treatment for systemic sclerosis-associated interstitial lung disease. <i>Current Opinion in Rheumatology</i> , 2021 , 33, 240-248	5.3	8
405	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 209-221	10.2	30
404	Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol. <i>BMJ Open</i> , 2021 , 11, e044765	3	2
403	Intensive and app-delivered occupational therapy to improve upper extremity function in early diffuse cutaneous systemic sclerosis: a pilot two-arm trial. <i>Rheumatology</i> , 2021 , 60, 5002-5011	3.9	1
402	Factors Influencing Patient Decision-Making Concerning Treatment Escalation in Raynaud's Phenomenon Secondary to Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2021 , 73, 1845-1852	4.7	1

401	Expansion of FCGR3A macrophages, FCN1 mo-DC, and plasmacytoid dendritic cells associated with severe skin disease in systemic sclerosis. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	3
400	A Practical Approach to the Management of Digital Ulcers in Patients With Systemic Sclerosis: A Narrative Review. <i>JAMA Dermatology</i> , 2021 , 157, 851-858	5.1	3
399	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. <i>Journal of Rheumatology</i> , 2021 , 48, 1698-1717	4.1	2
398	Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1301-1310	9.5	37
397	New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 635-652	5.9	4
396	Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1523-1532	9.5	10
395	Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1453-1460	2.4	8
394	Rational repurposing of tocilizumab for treatment of lung fibrosis in systemic sclerosis. <i>Lancet Rheumatology, The</i> , 2021 , 3, e321-e323	14.2	1
393	Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. <i>Arthritis Research and Therapy</i> , 2021 , 23, 170	5.7	4
392	Integrating new therapies for systemic sclerosis-associated lung fibrosis in clinical practice. <i>Lancet Respiratory Medicine, the</i> , 2021 , 9, 560-562	35.1	2
391	Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial. <i>BMJ Open</i> , 2021 , 11, e048541	3	1
390	Rehabilitation Interventions in Systemic Sclerosis: A Systematic Review and Future Directions. <i>Arthritis Care and Research</i> , 2021 ,	4.7	2
389	Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	10
388	Rituximab for the treatment of systemic sclerosis: urgent need for an international randomised controlled trial. <i>Lancet Rheumatology, The</i> , 2021 , 3, e463-e465	14.2	2
387	Dissecting the Cellular Mechanism of Prostacyclin Analog Iloprost in Reversing Vascular Dysfunction in Scleroderma. <i>Arthritis and Rheumatology</i> , 2021 , 73, 520-529	9.5	9
386	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 66-76	2.3	2
385	Fatigue Predicts Future Reduced Social Participation, not Reduced Physical Function or Quality of Life in People with Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 187-193	2.3	4
384	Rituximab for the treatment of systemic sclerosis-interstitial lung disease. <i>Rheumatology</i> , 2021 , 60, 489-491	5.9	6

383	New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 641-650	2.4	7
382	Development of a Musculoskeletal Ultrasound Protocol to Examine Upper Extremity Rehabilitation Outcomes in Systemic Sclerosis. <i>Journal of Diagnostic Medical Sonography</i> , 2021 , 37, 13-23	0.4	1
381	Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1005-1013	9.5	5
380	Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and II. <i>ACR Open Rheumatology</i> , 2021 , 3, 8-16	3.5	1
379	Does hand involvement in systemic sclerosis limit completion of patient-reported outcome measures?. <i>Clinical Rheumatology</i> , 2021 , 40, 965-971	3.9	1
378	Fatigue and Its Association With Social Participation, Functioning, and Quality of Life in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2021 , 73, 415-422	4.7	13
377	UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract (GIT) 2.0 Reflux Scale Correlates With Impaired Esophageal Scintigraphy Findings in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021 , 48, 1422-1426	4.1	1
376	How do patients define Raynaud's phenomenon? Differences between primary and secondary disease. <i>Clinical Rheumatology</i> , 2021 , 40, 1611-1616	3.9	3
375	Clinical and psychosocioeconomic impact of COVID-19 pandemic on patients of the Indian Progressive Systemic Sclerosis Registry (IPSSR). <i>Rheumatology Advances in Practice</i> , 2021 , 5, rkab027	1.1	1
374	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSICIS trial. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 96-106	35.1	38
373	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	10
372	Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis. <i>Genome Medicine</i> , 2021 , 13, 35	14.4	6
371	THE ROLE OF CHEST CT IN DECIPHERING INTERSTITIAL LUNG INVOLVEMENT: SYSTEMIC SCLEROSIS VERSUS COVID-19. <i>Rheumatology</i> , 2021 ,	3.9	15
370	Genome-Wide Reduction in Chromatin Accessibility and Unique Transcription Factor Footprints in Endothelial Cells and Fibroblasts in Scleroderma Skin. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1501-1513	9.5	3
369	Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1731-1737	9.5	5
368	The association between hand disease severity and fatigue in individuals with systemic sclerosis: a scoping review. <i>Disability and Rehabilitation</i> , 2021 , 1-7	2.4	0
367	Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. <i>Clinical Reviews in Allergy and Immunology</i> , 2021 , 1	12.3	2
366	Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody status and skin score. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	5

365	Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies. <i>Vaccine</i> , 2021 , 39, 6111-6116	4.1	20
364	A Case of Recalcitrant Linear Morphea Responding to Subcutaneous Abatacept. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 194-198	2.3	0
363	Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021 , 23, 10	5.7	4
362	Interstitial lung disease in systemic sclerosis quantification of disease classification and progression with high-resolution computed tomography: An observational study.. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 154-164	2.3	4
361	Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USA. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 43-51	2.2	1
360	Osteopontin Links Myeloid Activation and Disease Progression in Systemic Sclerosis. <i>Cell Reports Medicine</i> , 2020 , 1, 100140	18	14
359	Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II. <i>ACR Open Rheumatology</i> , 2020 , 2, 362-370	3.5	9
358	2020 American College of Rheumatology Guideline for the Management of Gout. <i>Arthritis and Rheumatology</i> , 2020 , 72, 879-895	9.5	82
357	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 724-726	2.4	38
356	2020 American College of Rheumatology Guideline for the Management of Gout. <i>Arthritis Care and Research</i> , 2020 , 72, 744-760	4.7	157
355	The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 963-967	5.3	2
354	Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 891-896	5.3	6
353	Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 61-71	2.3	26
352	Management of systemic sclerosis: the first five years. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 228-237	3.3	15
351	Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1049-1058	9.5	19
350	Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1892-1896	9.5	12
349	Patient experiences of digital ulcer development and evolution in systemic sclerosis. <i>Rheumatology</i> , 2020 , 59, 2156-2158	3.9	7
348	Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. <i>Journal of Clinical Investigation</i> , 2020 , 130, 2451-2464	15.9	47

347	Treatment of systemic sclerosis associated ILD: Lessons from clinical trials. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 61-71	2.3	12
346	Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry. <i>Clinical Rheumatology</i> , 2020 , 39, 93-102	3.9	3
345	Performance of Anti-Topoisomerase I Antibody Testing by Multiple-Bead, Enzyme-Linked Immunosorbent Assay and Immunodiffusion in a University Setting. <i>Journal of Clinical Rheumatology</i> , 2020 , 26, 115-118	1.1	5
344	Psychometric validation of the Hand Disability in Systemic Sclerosis-Digital Ulcers (HDISS-DU ²) patient-reported outcome instrument. <i>Arthritis Research and Therapy</i> , 2020 , 22, 3	5.7	6
343	Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 650-660	10.2	41
342	Validity and correlates of the Brief Satisfaction With Appearance Scale for patients with limited and diffuse systemic sclerosis: Analysis from the University of California, Los Angeles Scleroderma Quality of Life Study.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 143-151	2.3	1
341	Multicenter Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2020 , 72, 723-733	4.7	14
340	Development and Pilot Testing of MyGoutCare: A Novel Web-Based Platform to Educate Patients With Gout. <i>Journal of Clinical Rheumatology</i> , 2020 , 26, 320-326	1.1	2
339	Patient-reported outcome instruments in clinical trials of systemic sclerosis.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 90-102	2.3	8
338	Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 379-386 ^{2.4}	2.4	33
337	Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials. <i>Expert Opinion on Emerging Drugs</i> , 2020 , 25, 455-466	3.7	4
336	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.. <i>Lancet Rheumatology, The</i> , 2020 , 2, e743-e753	14.2	13
335	Assessment of skin disease in scleroderma: Practices and opinions of investigators studying scleroderma.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 167-171	2.3	2
334	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1333-1339	2.4	16
333	Response to: 'Riociguat in systemic sclerosis: a potential for disease modification' by Jain and Dhir. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	
332	Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatment. <i>Current Treatment Options in Rheumatology</i> , 2020 , 6, 337-353	1.3	10
331	A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1600-1607	2.4	25
330	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine, the</i> , 2020 , 8, 963-974	35.1	112

329	Patient perception of disease burden in diffuse cutaneous systemic sclerosis.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 66-76	2.3	3
328	Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2020 , 72, 316-325	9.5	10
327	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020 , 72, 125-136	9.5	92
326	and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 552-562	11.5	23
325	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 618-625	2.4	30
324	A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. <i>Arthritis Research and Therapy</i> , 2019 , 21, 202	5.7	10
323	Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). <i>Arthritis Research and Therapy</i> , 2019 , 21, 23	5.7	15
322	Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1242-1248	2.4	18
321	Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. <i>Arthritis and Rheumatology</i> , 2019 , 71, 2059-2067	9.5	29
320	Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. <i>RMD Open</i> , 2019 , 5, e000826	5.9	16
319	Capillary Proliferation in Systemic-Sclerosis-Related Pulmonary Fibrosis: Association with Pulmonary Hypertension. <i>ACR Open Rheumatology</i> , 2019 , 1, 26-36	3.5	4
318	Identification of Cysteine-Rich Angiogenic Inducer 61 as a Potential Antifibrotic and Proangiogenic Mediator in Scleroderma. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1350-1359	9.5	10
317	Insight into the Contrasting Findings of Therapeutic Trials of Digital Ischaemic Manifestations of Systemic Sclerosis. <i>Current Treatment Options in Rheumatology</i> , 2019 , 5, 85-103	1.3	6
316	Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 1036-1040	2.3	6
315	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 648-656	2.4	43
314	Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds. <i>ACS Pharmacology and Translational Science</i> , 2019 , 2, 92-100	5.9	12
313	5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 4350-4369	8.3	21
312	Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. <i>Journal of Rheumatology</i> , 2019 , 46, 1316-1325	4.1	18

311	Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 3695-3702	11.5	44
310	Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. <i>Rheumatology</i> , 2019 , 58, 567-579	3.9	35
309	An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups. <i>Journal of Scleroderma and Related Disorders</i> , 2019 , 4, 17-27	2.3	10
308	Randomized Controlled Trial to Evaluate an Internet-Based Self-Management Program in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2019 , 71, 435-447	4.7	14
307	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1151-1159	2.4	344
306	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1400-1412	9.5	488
305	Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	24
304	Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1339-1349	9.5	34
303	Management of systemic sclerosis-associated interstitial lung disease. <i>Current Opinion in Rheumatology</i> , 2019 , 31, 241-249	5.3	38
302	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019 , 46, 721-726	4.1	29
301	Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 122-130	2.4	88
300	Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease - Scleroderma Clinical Trials Consortium. <i>Journal of Rheumatology</i> , 2019 , 46, 78-84	4.1	7
299	Reply. <i>Arthritis and Rheumatology</i> , 2019 , 71, 327-328	9.5	
298	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019 , 71, 964-971	9.5	21
297	Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. <i>Arthritis Research and Therapy</i> , 2019 , 21, 8	5.7	10
296	Response to: 'Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series' by NarvBz. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e124	2.4	6
295	Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 1059-1067	5.3	18
294	Diagnosis of pulmonary hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	175

293	Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. <i>Journal of Rheumatology</i> , 2019 , 46, 176-183	4.1	14
292	The patient experience of Raynaud's phenomenon in systemic sclerosis. <i>Rheumatology</i> , 2019 , 58, 18-26	3.9	26
291	Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 686-693	5.3	16
290	Reliability, construct validity and responsiveness to change of the PROMIS-29 in systemic sclerosis-associated interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 119, 49-56	2.2	1
289	Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2018 , 70, 1373-1384	4.7	38
288	Occupational Therapy Treatment to Improve Upper Extremity Function in Individuals with Early Systemic Sclerosis: A Pilot Study. <i>Arthritis Care and Research</i> , 2018 , 70, 1653-1660	4.7	11
287	Screening High-Resolution Computed Tomography of the Chest to Detect Interstitial Lung Disease in Systemic Sclerosis: A Global Survey of Rheumatologists. <i>Arthritis and Rheumatology</i> , 2018 , 70, 971-972	9.5	24
286	Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018 , 57, 813-817	3.9	14
285	Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. <i>New England Journal of Medicine</i> , 2018 , 378, 35-47	59.2	266
284	Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials. <i>Arthritis Care and Research</i> , 2018 , 70, 439-444	4.7	35
283	Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 128-132	2.4	17
282	Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018 , 57, 152-157	3.9	7
281	Establishing clinical severity for PROMIS measures in adult patients with rheumatic diseases. <i>Quality of Life Research</i> , 2018 , 27, 755-764	3.7	35
280	Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1654-1660	9.5	8
279	Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1634-1643	9.5	49
278	Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1362-1371	2.4	71
277	Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations. <i>PLoS ONE</i> , 2018 , 13, e0189498	3.7	15
276	pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis. <i>JCI Insight</i> , 2018 , 3,	9.9	24

275	Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 212-220	2.4	172
274	Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 644-652	10.2	47
273	Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II. <i>Annals of the American Thoracic Society</i> , 2018 , 15, 1286-1295	4.7	48
272	Burden of Gastrointestinal Symptoms in the United States: Results of a Nationally Representative Survey of Over 71,000 Americans. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1701-1710	0.7	56
271	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report. <i>Journal of Scleroderma and Related Disorders</i> , 2018 , 3, 249-252	2.3	25
270	Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1208-1218	2.4	25
269	Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). <i>Chest</i> , 2018 , 154, 862-871	5.3	47
268	Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2018 , 70, 912-919	9.5	18
267	Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 113, 146-149	2.2	11
266	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. <i>Body Image</i> , 2017 , 20, 99-106	7.4	3
265	Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 1186-1192	4	27
264	Pharmacokinetic optimization of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic sclerosis. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017 , 27, 1744-1749	2.9	26
263	Systemic sclerosis. <i>Lancet, The</i> , 2017 , 390, 1685-1699	40	764
262	Structural Validity of the Rheumatology Attitudes Index in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study. <i>Journal of Rheumatology</i> , 2017 , 44, 795-798	4.1	
261	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. <i>Rheumatology</i> , 2017 , 56, 1302-1311	3.9	34
260	Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1903-1913	8.5	92
259	Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1451-1460	9.5	67
258	Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort. <i>Journal of Rheumatology</i> , 2017 , 44, 791-794	4.1	8

257	Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II. <i>Chest</i> , 2017 , 151, 813-820	5.3	35
256	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1327-1339	2.4	497
255	Points to consider when doing a trial primarily involving the heart. <i>Rheumatology</i> , 2017 , 56, v12-v16	3.9	5
254	Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials. <i>Rheumatology</i> , 2017 , 56, v33-v37	3.9	4
253	Interstitial lung disease points to consider for clinical trials in systemic sclerosis. <i>Rheumatology</i> , 2017 , 56, v27-v32	3.9	20
252	Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta. <i>Rheumatology</i> , 2017 , 56, 1970-1981	3.9	32
251	Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis. <i>Rheumatology</i> , 2017 , 56, v4-v11	3.9	5
250	Muscle involvement in systemic sclerosis: points to consider in clinical trials. <i>Rheumatology</i> , 2017 , 56, v38-v44	3.9	19
249	Points to consider in renal involvement in systemic sclerosis. <i>Rheumatology</i> , 2017 , 56, v49-v52	3.9	10
248	Assessment of skin involvement in systemic sclerosis. <i>Rheumatology</i> , 2017 , 56, v53-v66	3.9	32
247	Points to consider-Raynaud's phenomenon in systemic sclerosis. <i>Rheumatology</i> , 2017 , 56, v45-v48	3.9	19
246	Points to consider for skin ulcers in systemic sclerosis. <i>Rheumatology</i> , 2017 , 56, v67-v71	3.9	37
245	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) definition. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 115-120 ²⁻³	2.3	49
244	Response to Screening for Pulmonary Hypertension in Scleroderma. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, e6-e6	2.3	
243	Health care utilization in patients with gout: a prospective multicenter cohort study. <i>BMC Musculoskeletal Disorders</i> , 2017 , 18, 233	2.8	6
242	Racial differences in health-related quality of life and functional ability in patients with gout. <i>Rheumatology</i> , 2017 , 56, 103-112	3.9	10
241	RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. <i>Respiratory Medicine</i> , 2017 , 122 Suppl 1, S14-S17	3.17	24
240	Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database. <i>Medicine (United States)</i> , 2017 , 96, e8980	1.8	47

239	Functional disability and other health-related quality-of-life domains: points to consider for clinical trials in systemic sclerosis. <i>Rheumatology</i> , 2017 , 56, v17-v22	3.9	11
238	Points to consider for designing trials in systemic sclerosis patients with arthritic involvement. <i>Rheumatology</i> , 2017 , 56, v23-v26	3.9	6
237	Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 11-18	2.3	190
236	Tocilizumab Treatment of Patients with Systemic Sclerosis: Clinical Data. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, S29-S35	2.3	6
235	Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 42-49	2.3	18
234	Measuring Disease Activity and Outcomes in Clinical Trials 2017 , 637-648		
233	Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 106, 106-113	2.2	7
232	A right ventricular diastolic impairment is common in systemic sclerosis and is associated with other target-organ damage. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 439-45	5.3	18
231	Health State Utilities and Disease Duration in Systemic Sclerosis: Is There an Association?. <i>Journal of Rheumatology</i> , 2016 , 43, 1832-1837	4.1	3
230	Hand Impairment in Systemic Sclerosis: Various Manifestations and Currently Available Treatment. <i>Current Treatment Options in Rheumatology</i> , 2016 , 2, 252-269	1.3	33
229	Gastrointestinal Manifestations of Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2016 , 1, 247-256	2.3	75
228	Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. <i>Arthritis Research and Therapy</i> , 2016 , 18, 305	5.7	42
227	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2016 , 68, 167-78	4.7	10
226	Using Optimal Test Assembly Methods for Shortening Patient-Reported Outcome Measures: Development and Validation of the Cochin Hand Function Scale-6: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2016 , 68, 1704-1713	4.7	15
225	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. <i>Arthritis Research and Therapy</i> , 2016 , 18, 20	5.7	13
224	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 299-311	9.5	69
223	Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 374-814	2.4	55
222	Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1367-71	2.4	29

221	A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift. <i>Postgraduate Medicine</i> , 2016 , 128, 34-40	3.7	22
220	Performance of Gout Impact Scale in a longitudinal observational study of patients with gout. <i>Rheumatology</i> , 2016 , 55, 982-90	3.9	9
219	Scleroderma dermal microvascular endothelial cells exhibit defective response to pro-angiogenic chemokines. <i>Rheumatology</i> , 2016 , 55, 745-54	3.9	21
218	A Randomized Controlled Trial of Acupressure for the Treatment of Raynaud's Phenomenon: The difficulty of conducting a trial in Raynaud's phenomenon. <i>Journal of Scleroderma and Related Disorders</i> , 2016 , 1, 226-233	2.3	3
217	Systemic Sclerosis Trial Design Moving Forward. <i>Journal of Scleroderma and Related Disorders</i> , 2016 , 1, 177-180	2.3	34
216	Emerging strategies for treatment of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2016 , 1, 186-193	2.3	36
215	An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. <i>Journal of Rheumatology</i> , 2016 , 43, 1672-9	4.1	163
214	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. <i>Arthritis Care and Research</i> , 2016 , 68, 667-72	4.7	37
213	Management of connective tissue diseases associated interstitial lung disease: a review of the published literature. <i>Current Opinion in Rheumatology</i> , 2016 , 28, 236-45	5.3	52
212	Characterisation of an epigenetically altered CD4(+) CD28(+) Kir(+) T cell subset in autoimmune rheumatic diseases by multiparameter flow cytometry. <i>Lupus Science and Medicine</i> , 2016 , 3, e000147	4.6	15
211	Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center Experience. <i>Annals of the American Thoracic Society</i> , 2016 , 13, 793-802	4.7	52
210	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. <i>Lancet, The</i> , 2016 , 387, 2630-2640	4.0	359
209	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1975-88	27.4	74
208	Impact of National Institutes of Health Gastrointestinal PROMIS Measures in Clinical Practice: Results of a Multicenter Controlled Trial. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1546-1556	0.7	17
207	Histone Deacetylase 5 Is Overexpressed in Scleroderma Endothelial Cells and Impairs Angiogenesis via Repression of Proangiogenic Factors. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2975-2985	9.5	46
206	Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016 , 68, 907-13	4.7	16
205	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 708-719	35.1	487
204	Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. <i>Rheumatology</i> , 2015 , 54, 144-51	3.9	27

203	Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group. <i>Journal of Rheumatology</i> , 2015 , 42, 2168-71	4.1	99
202	Evaluation of the Satisfaction with Appearance Scale and Its Short Form in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study. <i>Journal of Rheumatology</i> , 2015 , 42, 1624-30	4.1	14
201	Antinuclear antibody-negative systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 44, 680-6	5.3	43
200	Distinctions between diagnostic and classification criteria?. <i>Arthritis Care and Research</i> , 2015 , 67, 891-7	4.7	268
199	Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1124-31	2.4	76
198	Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014. <i>Current Opinion in Rheumatology</i> , 2015 , 27, 241-8	5.3	25
197	Systemic sclerosis: commonly asked questions by rheumatologists. <i>Journal of Clinical Rheumatology</i> , 2015 , 21, 149-55	1.1	11
196	Screening and Early Detection of Pulmonary Arterial Hypertension in Connective Tissue Diseases. It Is Time to Institute It!. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 1032-3	10.2	6
195	Activation of the Thromboxane A2 Receptor by 8-Isoprostane Inhibits the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Scleroderma. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 3153-3162 ¹⁹	4.3	19
194	Old medications and new targeted therapies in systemic sclerosis. <i>Rheumatology</i> , 2015 , 54, 1944-53	3.9	36
193	Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis. <i>Arthritis and Rheumatology</i> , 2015 , 67, 3016-26	9.5	87
192	Health-related quality of life and treatment satisfaction in patients with gout: results from a cross-sectional study in a managed care setting. <i>Patient Preference and Adherence</i> , 2015 , 9, 971-81	2.4	18
191	Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1612-20	2.4	115
190	Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report. <i>Journal of Medical Case Reports</i> , 2015 , 9, 136	1.2	4
189	Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2015 , 54, 1369-79	3.9	17
188	Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. <i>Arthritis Research and Therapy</i> , 2015 , 17, 372	5.7	61
187	Specificity of Systemic Sclerosis Classification Criteria. <i>Journal of Rheumatology</i> , 2015 , 42, 2512	4.1	3
186	Imaging as an Outcome Measure in Gout Studies: Report from the OMERACT Gout Working Group. <i>Journal of Rheumatology</i> , 2015 , 42, 2460-4	4.1	32

185	Management of gastrointestinal involvement in scleroderma. <i>Current Treatment Options in Rheumatology</i> , 2015 , 1, 82-105	1.3	48
184	Clinical Outcome Measures in Raynaud's Phenomenon 2015 , 279-286		
183	Assessing disease activity and outcome in systemic sclerosis (scleroderma) 2015 , 1159-1164		
182	What tests should you use to assess small intestinal bacterial overgrowth in systemic sclerosis? <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S117-22	2.2	7
181	Treatment of acute gout: a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 44, 31-8	5.3	56
180	Examining radiographic outcomes over time. <i>Rheumatology International</i> , 2014 , 34, 271-9	3.6	4
179	Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014 , 349, 480-6	4.7	80
178	Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis. <i>Clinical Rheumatology</i> , 2014 , 33, 207-14	3.9	43
177	Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 43, 536-41	5.3	15
176	Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease. <i>Arthritis and Rheumatology</i> , 2014 , 66, 1900-8	9.5	34
175	Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1340-9	2.4	444
174	Cardiac arrhythmias and conduction defects in systemic sclerosis. <i>Rheumatology</i> , 2014 , 53, 1172-7	3.9	58
173	Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription. <i>American Journal of Physiology - Cell Physiology</i> , 2014 , 307, C2-13	5.4	52
172	Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis. <i>Thorax</i> , 2014 , 69, 123-9	7.3	47
171	GERD symptoms in the general population: prevalence and severity versus care-seeking patients. <i>Digestive Diseases and Sciences</i> , 2014 , 59, 2488-96	4	33
170	ImmunoChip analysis identifies multiple susceptibility loci for systemic sclerosis. <i>American Journal of Human Genetics</i> , 2014 , 94, 47-61	11	151
169	Development of an online library of patient-reported outcome measures in gastroenterology: the GI-PRO database. <i>American Journal of Gastroenterology</i> , 2014 , 109, 234-48	0.7	17
168	Connective tissue disease-associated interstitial pneumonia and idiopathic interstitial pneumonia: similarity and difference. <i>Seminars in Ultrasound, CT and MRI</i> , 2014 , 35, 29-38	1.7	22

167	Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 43, 666-72	5.3	92
166	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014 , 67, 706-14	5.7	40
165	Lipoic acid plays a role in scleroderma: insights obtained from scleroderma dermal fibroblasts. <i>Arthritis Research and Therapy</i> , 2014 , 16, 411	5.7	16
164	Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis. <i>Arthritis Care and Research</i> , 2014 , 66, 1731-9	4.7	22
163	Item response theory, computerized adaptive testing, and PROMIS: assessment of physical function. <i>Journal of Rheumatology</i> , 2014 , 41, 153-8	4.1	118
162	Prevalence of subclinical atherosclerosis is increased in systemic sclerosis and is associated with serum proteins: a cross-sectional, controlled study of carotid ultrasound. <i>Rheumatology</i> , 2014 , 53, 704-13	3.9	31
161	Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. <i>Arthritis Research and Therapy</i> , 2014 , 16, 493	5.7	36
160	Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1804-14	0.7	123
159	Outcome measures in acute gout: a systematic literature review. <i>Journal of Rheumatology</i> , 2014 , 41, 558-68	4.1	20
158	Il buono, il brutto, il cattivo. <i>Thorax</i> , 2014 , 69, 871-2	7.3	
157	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. <i>Thorax</i> , 2014 , 69, 428-36	7.3	75
156	OMERACT endorsement of measures of outcome for studies of acute gout. <i>Journal of Rheumatology</i> , 2014 , 41, 569-73	4.1	19
155	Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. <i>Arthritis Care and Research</i> , 2014 , 66, 489-95	4.7	100
154	Taking charge of systemic sclerosis: a pilot study to assess the effectiveness of an internet self-management program. <i>Arthritis Care and Research</i> , 2014 , 66, 778-82	4.7	29
153	Interstitial lung disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. <i>Annals of the American Thoracic Society</i> , 2014 , 11 Suppl 3, S169-77	4.7	29
152	Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis. <i>Arthritis Care and Research</i> , 2014 , 66, 1725-30	4.7	19
151	Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat. <i>Postgraduate Medicine</i> , 2014 , 126, 65-75	3.7	17
150	Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. <i>Journal of Rheumatology</i> , 2014 , 41, 99-105	4.1	62

149	Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 44, 55-62	5.3	56
148	Gastrointestinal Involvement in Systemic Sclerosis 2014 , 77-87		
147	Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: utility of the University of California, San Diego, Shortness of Breath Questionnaire. <i>Arthritis Care and Research</i> , 2013 , 65, 454-63	4.7	14
146	Combination of echocardiographic and pulmonary function test measures improves sensitivity for diagnosis of systemic sclerosis-associated pulmonary arterial hypertension: analysis of 2 cohorts. <i>Journal of Rheumatology</i> , 2013 , 40, 1706-11	4.1	17
145	2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2737-47		1636
144	Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. <i>Arthritis and Rheumatism</i> , 2013 , 65, 3194-201		131
143	Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. <i>Rheumatology</i> , 2013 , 52, 1809-17	3.9	71
142	Definitions and diagnosis of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2013 , 62, D42-50	15.1	1163
141	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1747-55	2.4	1109
140	Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials. <i>Arthritis Care and Research</i> , 2013 , 65, 630-6	4.7	26
139	The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. <i>BMJ Open</i> , 2013 , 3,	3	82
138	Long-term safety of pegloticase in chronic gout refractory to conventional treatment. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1469-74	2.4	69
137	Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2917-27		28
136	Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations. <i>European Respiratory Review</i> , 2013 , 22, 515-25	9.8	20
135	A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria. <i>Journal of Rheumatology</i> , 2013 , 40, 498-505	4.1	22
134	Measuring response in the gastrointestinal tract in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2013 , 25, 700-6	5.3	41
133	Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial. <i>Journal of Rheumatology</i> , 2013 , 40, 455-60	4.1	54
132	Outcome measures in gout 2013 , 108-123		

131	Treatment of early diffuse systemic sclerosis skin disease. <i>Clinical and Experimental Rheumatology</i> , 2013 , 31, 166-71	2.2	29
130	Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2013 , 31, 57-63	2.2	12
129	Arthritis in systemic sclerosis: systematic review of the literature and suggestions for the performance of future clinical trials in systemic sclerosis arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2012 , 41, 801-14	5.3	28
128	Work productivity in scleroderma: analysis from the University of California, Los Angeles scleroderma quality of life study. <i>Arthritis Care and Research</i> , 2012 , 64, 176-83	4.7	19
127	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. <i>Arthritis Care and Research</i> , 2012 , 64, 351-7	4.7	41
126	Validation of potential classification criteria for systemic sclerosis. <i>Arthritis Care and Research</i> , 2012 , 64, 358-67	4.7	64
125	Articular involvement in systemic sclerosis. <i>Rheumatology</i> , 2012 , 51, 1347-56	3.9	56
124	Small and Large Intestinal Involvement 2012 , 485-499		1
123	Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. <i>Health and Quality of Life Outcomes</i> , 2012 , 10, 117	3	112
122	2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. <i>Arthritis Care and Research</i> , 2012 , 64, 1447-61	4.7	507
121	Treatment of Interstitial Lung Disease 2012 , 421-427		1
120	Measuring Disease Activity and Outcomes in Clinical trials 2012 , 661-671		1
119	Feasibility and construct validity of PROMIS and "legacy" instruments in an academic scleroderma clinic. <i>Value in Health</i> , 2012 , 15, 128-34	3.3	59
118	2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. <i>Arthritis Care and Research</i> , 2012 , 64, 1431-46	4.7	1061
117	An association study of disease activity score components and patient satisfaction with overall health for early RA patients on non-biologic DMARD therapy. <i>Rheumatology International</i> , 2012 , 32, 2725-9	3.6	6
116	Health-Related Quality of Life and Outcome Measures in Gout 2012 , 217-225		1
115	Disease modification and other trials in systemic sclerosis have come a long way, but have to go further. <i>Arthritis Care and Research</i> , 2012 , 64, 955-9	4.7	2
114	2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012 , 64, 625-39	4.7	1199

113	Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. <i>Journal of Rheumatology</i> , 2012 , 39, 1450-7	4.1	45
112	Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. <i>Journal of Rheumatology</i> , 2012 , 39, 1326-33	4.1	57
111	Early detection and management of pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2012 , 21, 306-12	9.8	67
110	Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1335-42	2.4	67
109	IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1197-202	2.4	66
108	New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). <i>Clinical and Experimental Rheumatology</i> , 2012 , 30, S23-9	2.2	26
107	American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 404-13	2.4	518
106	Adverse events during the Scleroderma Lung Study. <i>American Journal of Medicine</i> , 2011 , 124, 459-67	2.4	24
105	Patterns of radiographic outcomes in early, seropositive rheumatoid arthritis: a baseline analysis. <i>Contemporary Clinical Trials</i> , 2011 , 32, 160-8	2.3	4
104	Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial. <i>Journal of Rheumatology</i> , 2011 , 38, 990-6	4.1	38
103	Methods of formal consensus in classification/diagnostic criteria and guideline development. <i>Seminars in Arthritis and Rheumatism</i> , 2011 , 41, 95-105	5.3	204
102	Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis. <i>Clinical Immunology</i> , 2011 , 141, 293-303	9	17
101	Health-related quality of life in adults reporting arthritis: analysis from the National Health Measurement Study. <i>Quality of Life Research</i> , 2011 , 20, 1131-40	3.7	18
100	The future of measuring patient-reported outcomes in rheumatology: Patient-Reported Outcomes Measurement Information System (PROMIS). <i>Arthritis Care and Research</i> , 2011 , 63 Suppl 11, S486-90	4.7	99
99	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011 , 63, 573-86		520
98	Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis. <i>Arthritis and Rheumatism</i> , 2011 , 63, 2078-90		115
97	Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. <i>Arthritis and Rheumatism</i> , 2011 , 63, 2797-808		83
96	Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3078-85		85

95	A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3540-6		105
94	Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study. <i>Rheumatology</i> , 2011 , 50, 1280-7	3.9	42
93	Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. <i>Rheumatology</i> , 2011 , 50, 330-4	3.9	62
92	Minimally important differences of the gout impact scale in a randomized controlled trial. <i>Rheumatology</i> , 2011 , 50, 1331-6	3.9	28
91	Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 996-1002	2.4	54
90	Understanding gastrointestinal distress: a framework for clinical practice. <i>American Journal of Gastroenterology</i> , 2011 , 106, 380-5	0.7	27
89	Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. <i>Journal of Rheumatology</i> , 2011 , 38, 1920-4	4.1	40
88	Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. <i>Rheumatology</i> , 2011 , 50, 740-5	3.9	65
87	Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trials. <i>Rheumatology</i> , 2011 , 50, 335-42	3.9	26
86	Quality indicator set for systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, S33-9	2.2	8
85	Assessing disease activity and outcome in scleroderma 2011 , 1367-1371		3
84	A 54-Year Old Woman with Pain and Stiffness of Hands and Tendon Friction Rubs 2011 , 267-271		1
83	Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, S15-21	2.2	8
82	Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/ distention. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, S22-5	2.2	44
81	Predictors of doctor-rated and patient-rated gout severity: gout impact scales improve assessment. <i>Journal of Evaluation in Clinical Practice</i> , 2010 , 16, 1244-7	2.5	20
80	Gout disease-specific quality of life and the association with gout characteristics. <i>Patient Related Outcome Measures</i> , 2010 , 2010, 1-8	2.9	38
79	The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 588-91	2.4	43
78	Use of a medication control officer to reduce bias in a clinical trial: lessons learned from the scleroderma lung study. <i>Clinical Trials</i> , 2010 , 7, 85-9	2.2	

77	Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. <i>Rheumatology</i> , 2010 , 49, 955-9	3.9	41
76	Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2010 , 37, 550-7	4.1	9
75	An International, Web-Based, Prospective Cohort Study to Determine Whether the Use of ACE Inhibitors prior to the Onset of Scleroderma Renal Crisis Is Associated with Worse Outcomes-Methodology and Preliminary Results. <i>International Journal of Rheumatology</i> , 2010 ,	2	8
74	Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases. <i>Rheumatology</i> , 2010 , 49, 1184-8	3.9	40
73	Dr. Malaviya, et al reply. <i>Journal of Rheumatology</i> , 2010 , 37, 673-673	4.1	
72	Dr. Malaviya, et al reply. <i>Journal of Rheumatology</i> , 2010 , 37, 1543.1-1543	4.1	
71	Valuation of scleroderma and psoriatic arthritis health states by the general public. <i>Health and Quality of Life Outcomes</i> , 2010 , 8, 112	3	6
70	Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. <i>Ophthalmology</i> , 2010 , 117, 133-139.e2	7.3	124
69	Diagnosis and management of systemic sclerosis. <i>Indian Journal of Rheumatology</i> , 2010 , 5, 69-75	0.5	
68	Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design. <i>Current Rheumatology Reviews</i> , 2010 , 6, 138-144	1.6	21
67	Development of Clinical Trial Assessments for the Study of Interstitial Lung Disease in Patients who have Connective Tissue Diseases-Methodological Considerations. <i>Current Rheumatology Reviews</i> , 2010 , 6, 145-150	1.6	4
66	Evidence-based management of rapidly progressing systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010 , 24, 387-400	5.3	52
65	Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study. <i>Arthritis Care and Research</i> , 2010 , 62, 1772-8	4.7	26
64	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2582-91		182
63	Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities. <i>Arthritis and Rheumatism</i> , 2010 , 62, 3741-50		57
62	Screening and therapy for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel. <i>Clinical and Experimental Rheumatology</i> , 2010 , 28, S42-6	2.2	21
61	Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. <i>Clinical and Experimental Rheumatology</i> , 2010 , 28, S55-62	2.2	30
60	Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). <i>Journal of Rheumatology</i> , 2009 , 36, 2356-61	4.1	32

59	Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. <i>Chest</i> , 2009 , 136, 1333-1340	5.3	104
58	Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials. <i>Rheumatology</i> , 2009 , 48, 1143-6	3.9	33
57	Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study. <i>Rheumatology</i> , 2009 , 48, 1537-40	3.9	36
56	A randomized study of scleroderma health state values: a picture is worth a thousand words, and quite a few utiles. [corrected]. <i>Medical Decision Making</i> , 2009 , 29, 7-14	2.5	2
55	Validating and assessing the sensitivity of the Health Assessment Questionnaire-Disability Index-derived Short Form-6D in patients with early aggressive rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2009 , 36, 1150-7	4.1	9
54	Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report. <i>Journal of Rheumatology</i> , 2009 , 36, 1414-20	4.1	30
53	Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1102-11		108
52	Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. <i>Arthritis and Rheumatism</i> , 2009 , 60, 2490-8		86
51	Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1257-63		140
50	Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. <i>Arthritis and Rheumatism</i> , 2009 , 60, 3821-30		70
49	Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. <i>Current Rheumatology Reports</i> , 2009 , 11, 111-9	4.9	40
48	Systemic Sclerosis (Scleroderma) and Raynaud's Phenomenon 2009 , 77-95		
47	Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique. <i>JAMA Ophthalmology</i> , 2009 , 127, 1155-60		22
46	Perceptions of disease and health-related quality of life among patients with gout. <i>Rheumatology</i> , 2009 , 48, 582-6	3.9	83
45	Chapter 5 Gastrointestinal Involvement in Systemic Sclerosis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2008 , 8, 51-61	0.3	6
44	Oral cyclophosphamide for active scleroderma lung disease: a decision analysis. <i>Medical Decision Making</i> , 2008 , 28, 926-37	2.5	20
43	Willingness to pay for a cure in patients with chronic gout. <i>Medical Decision Making</i> , 2008 , 28, 606-13	2.5	13
42	Evaluation of an instrument assessing influence of Gout on health-related quality of life. <i>Journal of Rheumatology</i> , 2008 , 35, 2406-14	4.1	58

41	The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice. <i>Journal of Rheumatology</i> , 2008 , 35, 2339-43	4.1	72
40	The disutility of chronic gout. <i>Quality of Life Research</i> , 2008 , 17, 815-22	3.7	34
39	A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: coronary artery calcification in cases and controls. <i>Arthritis and Rheumatism</i> , 2008 , 59, 591-7		60
38	Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. <i>Arthritis and Rheumatism</i> , 2008 , 59, 699-705		85
37	Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database. <i>Journal of Rheumatology</i> , 2008 , 35, 1966-71	4.1	8
36	Does incorporation of aids and devices make a difference in the score of the health assessment questionnaire-disability index? Analysis from a scleroderma clinical trial. <i>Journal of Rheumatology</i> , 2008 , 35, 466-8	4.1	10
35	Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. <i>Arthritis and Rheumatism</i> , 2007 , 56, 323-33		360
34	Health values of patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2007 , 57, 86-93		48
33	Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. <i>Arthritis and Rheumatism</i> , 2007 , 56, 1676-84		82
32	Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. <i>Arthritis and Rheumatism</i> , 2007 , 57, 440-7		53
31	Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. <i>Arthritis and Rheumatism</i> , 2007 , 57, 1280-6		57
30	Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. <i>Quality of Life Research</i> , 2007 , 16, 1083-92	3.7	54
29	Outcome measures in systemic sclerosis: an update on instruments and current research. <i>Current Rheumatology Reports</i> , 2007 , 9, 151-7	4.9	49
28	Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 176, 1026-34	10.2	343
27	Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1633-40	2.4	23
26	Classifying radiographic progression status in early rheumatoid arthritis patients using propensity scores to adjust for baseline differences. <i>Statistical Methods in Medical Research</i> , 2007 , 16, 13-29	2.3	10
25	Natural products as a gold mine for arthritis treatment. <i>Current Opinion in Pharmacology</i> , 2007 , 7, 344-51	5.1	267
24	Systemic sclerosis - continuing progress in developing clinical measures of response. <i>Journal of Rheumatology</i> , 2007 , 34, 1194-200	4.1	58

23	Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. <i>Journal of Rheumatology</i> , 2007 , 34, 1459-64	4.1	61
22	Outcome evaluations in gout. <i>Journal of Rheumatology</i> , 2007 , 34, 1381-5	4.1	24
21	Health-related quality of life--an introduction. <i>American Journal of Managed Care</i> , 2007 , 13 Suppl 9, S218-23		59
20	Measuring process of arthritis care: the Arthritis Foundation's quality indicator set for rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2006 , 35, 211-37	5.3	35
19	Association of tumor necrosis factor alpha polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort. <i>Arthritis and Rheumatism</i> , 2006 , 54, 1105-16		44
18	Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. <i>Quality of Life Research</i> , 2006 , 15, 1383-94	3.7	24
17	COX-2 controversy: where are we and where do we go from here?. <i>Inflammopharmacology</i> , 2005 , 13, 395-402	5.1	14
16	Ayurvedic medicine: it is "time" for scientifically sound studies. <i>Seminars in Arthritis and Rheumatism</i> , 2005 , 34, 703-4	5.3	3
15	Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. <i>Arthritis and Rheumatism</i> , 2005 , 52, 592-600		108
14	Increased radiographic damage scores at the onset of seropositive rheumatoid arthritis in older patients are associated with osteoarthritis of the hands, but not with more rapid progression of damage. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2284-92		34
13	Validation of single-factor structure and scoring protocol for the Health Assessment Questionnaire-Disability Index. <i>Arthritis and Rheumatism</i> , 2005 , 53, 536-42		33
12	Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. <i>Journal of Rheumatology</i> , 2005 , 32, 832-40	4.1	101
11	Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients. <i>Journal of Rheumatology</i> , 2005 , 32, 1040-2	4.1	19
10	Scleroderma--developing measures of response. <i>Journal of Rheumatology</i> , 2005 , 32, 2477-80	4.1	14
9	Interaction between RANKL and HLA-DRB1 genotypes may contribute to younger age at onset of seropositive rheumatoid arthritis in an inception cohort. <i>Arthritis and Rheumatism</i> , 2004 , 50, 3093-103		41
8	Safety of tumour necrosis factor-alpha antagonists. <i>Drug Safety</i> , 2004 , 27, 307-24	5.1	141
7	Dating the "window of therapeutic opportunity" in early rheumatoid arthritis: accuracy of patient recall of arthritis symptom onset. <i>Journal of Rheumatology</i> , 2004 , 31, 1686-92	4.1	24
6	Gouty tophi in a pancreatic pseudocyst. <i>Arthritis and Rheumatism</i> , 2002 , 46, 565-6		6

- 5 Angiocentric T cell lymphoma of the central nervous system in a patient with Sjögren's syndrome. *Journal of Rheumatology*, **2002**, 29, 1548-50 4.1 5
- 4 Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. *Journal of Scleroderma and Related Disorders*, 239719832110644^{2,3} 1
- 3 Genome-wide reduction in chromatin accessibility and unique transcription factor footprints in endothelial cells and fibroblasts in scleroderma skin 1
- 2 Inhibition of histone readers bromodomain extra-terminal proteins alleviates scleroderma fibrosis 1
- 1 Identification of Pirin as a Molecular Target of the CCG-1423/CCG- 203971 Series of Anti-Fibrotic and Anti-Metastatic Compounds 1